

Ipilimumab-related toxicity: Management of hepatotoxicity

The safety and efficacy of ipilimumab have not been studied in patients with hepatic impairment. Based on the population pharmacokinetic results, no specific dose adjustment is necessary in patients with mild hepatic impairment (see SpC section 5.2) Ipilimumab must be administered with caution in patients with transaminase levels ≥ 5 x ULN or bilirubin levels > 3 x ULN at baseline

